Biosplice Submits First Potential Disease-Modifying Osteoarthritis Drug to FDA
Key Insights
Biosplice Therapeutics (search) has submitted a New Drug Application to the FDA for lorecivivint, marking the first potentially disease-modifying therapy for knee osteoarthritis to seek approval in the United States.
The Phase 3 OA-07 trial demonstrated that lorecivivint significantly improved pain at 6 months and both pain and function at 12 months compared to placebo, while also showing improvements in medial joint space width over two years.
The small-molecule drug targets DYRK1A and CLK2 (search) kinases and is administered as an intra-articular injection 1-2 times per year, with a safety profile similar to placebo across over 1,800 patients.
Biosplice Therapeutics (search) has submitted a New Drug Application (NDA) to the FDA for lorecivivint, potentially marking a historic milestone as the first disease-modifying therapy for knee osteoarthritis to seek regulatory approval in the United States. The small-molecule drug candidate demonstrated statistically and clinically significant improvements in pain, function, and joint structure in clinical trials spanning over a decade.
Pivotal Trial Results Show Dual Benefits
The 2-year Phase 3 OA-07 study revealed that patients treated with lorecivivint achieved significant pain improvement at 6 months and both pain and function improvements at 12 months compared to placebo. These symptomatic benefits were confirmed across multiple Phase 2 trials, establishing the drug's consistent therapeutic effect.
Beyond symptom relief, the OA-07 trial demonstrated rare structural benefits in osteoarthritis research. Patients treated with lorecivivint maintained and ultimately improved their medial joint space width (JSW) as measured by X-ray at two years following annual injections. Notably, placebo patients who experienced decreased medial JSW in the first year showed increases in joint space width after crossing over to active treatment with lorecivivint.
"After over a decade of clinical trials, we are pleased to be the first company to submit a data package in the US for a potentially disease-modifying drug in knee OA for approval," said Erich Horsley, CEO of Biosplice. "We are excited about the prospects of materially improving the OA patient's journey with a new treatment that is both safe and effective and has the potential to delay further structural progression."
Novel Mechanism Targets Disease Pathways
Lorecivivint operates through selective inhibition of two kinases: DYRK1A and CLK2 (search). DYRK1A is an inflammatory kinase whose inhibition results in significant reductions in multiple inflammatory cytokines and catabolic enzymes that break down hyaline cartilage. CLK2 inhibition alters local Wnt pathway signaling, which is believed to promote chondrocyte formation and protect hyaline cartilage.
The drug is formulated as a small-molecule suspension intended for intra-articular injection into the knee joint space, administered once or twice yearly. Biosplice initially synthesized and identified the novel compound in 2011, leading to an extensive clinical development program involving 11 clinical trials.
Safety Profile Matches Placebo
Throughout the decade-long clinical development program, lorecivivint's safety profile has remained consistent with and similar to placebo. Dr. Yusuf Yazici, Chief Medical Officer of Biosplice, noted that the company is "particularly excited by LOR's safety profile, which is similar to placebo across over 1,800 patients dosed, while demonstrating significant improvement in pain, function and structure."
The drug's safety is enhanced by its lack of detectable systemic exposure when injected into the knee joint, limiting potential side effects to the local treatment area.
Professor Tim McAlindon from UMass Chan School of Medicine (search), who advised Biosplice during the development program, commented: "It is rare to see a drug with LOR's safety profile, to say nothing of its disease-modifying potential. The unmet need in OA is well-known, and patients have not had access to novel treatments in decades."
Addressing Significant Unmet Medical Need
Osteoarthritis affects an estimated 50 million U.S. adults and over 500 million adults globally, making it the most common form of arthritis and a leading source of chronic pain and disability. Current estimates indicate approximately 25 million Americans, or 1 in 10 U.S. adults, have knee osteoarthritis specifically.
The disease burden extends beyond joint symptoms. Functional limitations are present in about 80% of people with osteoarthritis, and 25% are unable to perform major activities of daily living. Mortality rates are higher in patients with knee and hip osteoarthritis, largely due to cardiovascular disease, with increased risk associated with severity of walking disability. The FDA has recognized knee osteoarthritis as a 'serious condition' given both the increased morbidity and mortality.
Seth Ginsberg, Co-Founder and President of Global Healthy Living Foundation (search) and CreakyJoints (search), emphasized the potential impact: "Osteoarthritis affects more than 50 million Americans and remains one of the leading causes of pain, disability, and loss of independence worldwide. For patients, the disease shapes daily decisions, careers and quality of life, often over many years, while meaningful progress that addresses the disease itself rather than symptoms alone has remained out of reach."
Regulatory Pathway Forward
If approved, lorecivivint would represent the first disease-modifying therapy for osteoarthritis, a milestone long sought by patients, physicians, and researchers. The drug promises to deliver both near-term pain relief and long-term structural benefits to the millions of Americans living with knee osteoarthritis.
The FDA submission follows Biosplice's comprehensive clinical development program that has provided evidence for statistically and clinically significant improvements across multiple endpoints. The company's approach represents a shift from purely symptomatic treatments to addressing the underlying disease process in osteoarthritis.